| Author | Date | Design | yrs | N | BMD | Fxs | Markers | Comments |
| Ramsey-Goldman | 99 | retro | 4.5 since tx | 61 | . | 14.7% symptomatic | . | data from questionnaire |
| Glendenning | 99 | xs | 2.5 since TX | 32 | Z-score hip -.79, spine -2.39 | 7 (22%) vert fx, only 2 sympt. | increased, correlated with BMD | bxs variable |
| Boncimino | 99 | pros | 0.25 | 60 | fem -4.3%; spine -4.7% | . | ocal decreased, no change PTH , deoxypyr inc, 125D dec | Mg significantly assoicated with bone loss (inversely!) |
| Guo | 98 | xs | median 1 since tx | 50 | z score -.6 spine, -.5 fem | . | increased BAP, ocal, PTH, decr 125D, test | all men, apparently not on vit D Rx |
| Dopff | 98 | long | 0-2 since tx | 57 | . | . | hi PTH, hi CTX&ocalcin | . |
| Shane | 97 | pros | 3 | 70 | 1st year spine -7.3%, hip -10.5% | . | decre test, ocal, incr pyr | most loss during 1st year; ocal nadir @1mo, then rose again |
| Garcia-Delgado | 97 | RCT | 1.5 | 40 | baseline z -.99 to -1.65; 25vitD +4.9%, calcitonin -1.2%, etidronate -.2% | 4 in calcitonin, 3 in eti gp | PTH no change in any group, ocal up in all gps | calcitonin 100u/d; vitD32K/wk, all got Calcium, not blind; BMD showed decrease at 6 mo then increased again |
| Leidig-Bruckner | 97a | obs | 3.7 | 105 | . | 1st year 21%, 2nd 27%, 3rd 33% | . | . |
| Shane | 97a | obs | . | . | . | . | . | some pts lose despite antiresorptive Rx, esp at hip |
| Sambrook | 97a | db-bl | 2 | 66 | . | . | . | lung or heart; Rx calcitriol or calcium; 8 got hypercalcemia. Calcitriol -2%, calcium -5.8% at hip |
| Henderson | 97a | RCT | 0.5 | 41 | . | . | . | lung or heart; Rx calcitriol or eti; spine -3.7% in treated groups comp to historical control of -7%. By 12 mo -7%, control -9%. |
| Shane | 97a | . | . | . | . | . | . | treatment with eti. |
| VanCleemput | 96 | RCT | 2 | 48 | eti: spine-10%, hip -7; calcitriol spine -7, hip -5.6 | 4 symptomatic | . | eti vs calcitriol; lost bone hip and spine; 2nd year spine gained 1-2%, hip kept losing -3 to 7% |
| Thiebaue | 96 | pros | 1 | 48 | hip -8.5%, spine - 3.4% | . | PTH, osteocal up | . |
| Negri | 96 | xs | 3 sinc tx | 24 | z spine -.9, hip -1.2, similar men&women | 29% vert, don't mention sx | osteocal up, PTH up | more fxs with low fem BMD |
| Shane | 96 | pros | 1 | 47 | . | 36% of pts; most of spine, all but 2 symptomatic | . | most fx in first 6 months |
| Rozenberg | 95 | xs | 3 since tx | 98 | z spine -1.3, hip -.7 men, -1.2 women | previous study 5% symptomatic vert | . | . |
| Olivari | 95 | . | . | . | . | . | . | stopped steroids in a group (? if randomized) and they had better BMD than those still on steroids |
| Sambrook | 94 | pros | 1 | 25 | spine -8.8% | . | ocal down immediately, then up by one year; Test down, resorption markers up | . |
| Berguer | 94 | pros | 1 | 47 | spine -6%, hip -5.5% in 6 mo, spine more stable next 6 mo | . | . | excluded 5 pts with low BMD who got bisphos |
| Sambrook | 94 | . | . | . | . | . | . | same study reported in each journal |
| Lee | 94 | xs | 2 p tx | 31 | spine z 0, hip z-.89 | 8/31 (26%) don't mention sx | ocal up, nl test, nl vit D | AVN hip in 2 pts |
| Shane | 93 | xs | 2.5 p tx | 40 | spine -1.38 women, -.59 men; hip -1.41,-.77 | 0.35 | hi PTH, high osteocalcin | . |
| Meys | 98 | mixed | 2 | 123 | spine z=-.97 by 2 yrs p tx | . | . | pts with low BMD given fluoride which increased BMD |
| Muchmore | 92 | pros | up to 3 | 76 | QCT dec ~25% 6 mo, then stable x 2 yrs | 1/76 followed for over a year | . | some treated with calcitonin or hormones |
| Rich | 92 | xs | 3 p tx | 16 | . | 44% of pts clinical | . | . |